Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Larry Gibson

Neurology Hixson, TN Medical Doctor

NPI 1114013521 CMS profile 1248701

2051 Hamill Rd, Ste 301 B, Hixson, TN 37343

Open in the dashboard

General payments

$16,789

934 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Larry Gibson of Hixson, TN is reported in the CMS Open Payments database as having received $16,789 across 934 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,424 115
2024 General $2,539 123
2023 General $2,533 140
2022 General $2,864 157
2021 General $2,713 150
2020 General $1,635 96
2019 General $2,081 153

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Larry Gibson
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Larry Gibson were reported at $2,424. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Larry Gibson Neurology median Middle half National median
2019 $2,081 $474 $118–$2,177 $163
2020 $1,635 $367 $82–$2,309 $114
2021 $2,713 $438 $104–$2,547 $132
2022 $2,864 $442 $103–$2,388 $149
2023 $2,533 $464 $119–$2,312 $160
2024 $2,539 $468 $119–$2,323 $164
2025 $2,424 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neurocrine Biosciences, Inc. $1,327 69 payments
  2. Biogen, Inc. $1,284 71 payments
  3. Teva Pharmaceuticals USA, Inc. $1,064 61 payments
  4. AbbVie, Inc. $976 71 payments
  5. UCB, Inc. $798 37 payments
  6. ACADIA Pharmaceuticals Inc $796 48 payments
  7. Lundbeck LLC $739 36 payments
  8. Eisai Inc. $601 31 payments
  9. Avanir Pharmaceuticals, Inc. $568 58 payments
  10. Novartis Pharmaceuticals Corporation $536 27 payments
  11. Other $8,100 425 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,559 929 payments
  2. Education $230 5 payments
Products named General payments · program years 2019–2025
  1. INGREZZA $883 41 payments
  2. TYSABRI $695 37 payments
  3. ZEPOSIA $684 38 payments
  4. QULIPTA $682 47 payments
  5. UBRELVY $595 41 payments
  6. NUEDEXTA $568 58 payments
  7. Briviact $545 26 payments
  8. VALTOCO $507 24 payments
  9. NUPLAZID $501 28 payments
  10. NURTEC ODT $471 25 payments
  11. Other $12,123 655 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

2,698

Median for Neurology: 833

Drug cost

$608,172

Median for Neurology: $202,670

Branded share of claims

25.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rebif Interferon Beta-1a/Albumin Brand 14 $171,085
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 20 $106,960
Ingrezza Valbenazine Tosylate Brand 11 $83,830
Nurtec Odt Rimegepant Sulfate Brand 43 $64,623
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 26 $55,814
Qulipta Atogepant Brand 44 $47,561
Aimovig Autoinjector Erenumab-Aooe Brand 11 $7,772
Memantine Hcl Generic 212 $6,699
Lacosamide Generic 44 $6,494
Rivastigmine Generic 24 $6,263

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$88,169

Medicare's payments for the services billed

Medicare patients

510

Average age 75

Services billed

1,162

294 women, 216 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Diabetes 40%
Ischemic heart disease 38%
Chronic kidney disease 37%
Depression 37%
Alzheimer's or dementia 32%
Heart failure 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
$195 11 —
ZEPOSIA
$168 — —
VYVGART Hytrulo
$165 — —
Austedo XR
$147 — —
UBRELVY
$143 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

934 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record